Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.65
+1.31 (4.62%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Viridian Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-342.6-269.95-237.73-129.87-79.41
Upgrade
Depreciation & Amortization
0.460.540.520.260.12
Upgrade
Loss (Gain) From Sale of Assets
----0.08
Upgrade
Loss (Gain) From Sale of Investments
-6.76-15.66-11.49-0.210.96
Upgrade
Stock-Based Compensation
44.342.1567.1719.7714.47
Upgrade
Other Operating Activities
5.1716.790.267.49
Upgrade
Change in Accounts Receivable
---0.35-0.45
Upgrade
Change in Accounts Payable
6.56-0.07-12.0411.521.66
Upgrade
Change in Unearned Revenue
----0.290.64
Upgrade
Change in Other Net Operating Assets
16.479.672.624.38-0.12
Upgrade
Operating Cash Flow
-276.39-232.32-184.17-93.84-54.58
Upgrade
Capital Expenditures
-0.5-0.51-0.9-0.8-0.34
Upgrade
Sale of Property, Plant & Equipment
----0.08
Upgrade
Investment in Securities
-37.07-228.14-93.35-114.33-74.03
Upgrade
Investing Cash Flow
-37.56-228.65-94.25-115.13-74.29
Upgrade
Long-Term Debt Issued
28.88-155-
Upgrade
Total Debt Issued
28.88-155-
Upgrade
Net Debt Issued (Repaid)
28.88-155-
Upgrade
Issuance of Common Stock
366.99459.68146.79295.75116.59
Upgrade
Other Financing Activities
30.88-26.94-12.32-22.51-8.28
Upgrade
Financing Cash Flow
426.74457.74225.67322.24125.28
Upgrade
Net Cash Flow
112.79-3.23-52.75113.28-3.6
Upgrade
Free Cash Flow
-276.89-232.83-185.07-94.64-54.92
Upgrade
Free Cash Flow Margin
-390.81%-77096.03%-58938.85%-5340.58%-1853.49%
Upgrade
Free Cash Flow Per Share
-3.27-3.43-4.13-2.95-4.61
Upgrade
Cash Interest Paid
2.151.820.890.29-
Upgrade
Levered Free Cash Flow
-162.07-136.29-102.5-48.83-33.91
Upgrade
Unlevered Free Cash Flow
-158.98-134.92-101.66-48.52-33.91
Upgrade
Change in Working Capital
23.039.6-9.4315.961.72
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.